Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard Lee Weiner, M.D.

Co-Author

This page shows the publications co-authored by Howard Weiner and Shahamat Tauhid.
Connection Strength

1.983
  1. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.233
  2. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
    View in: PubMed
    Score: 0.222
  3. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Sep; 12:42-46.
    View in: PubMed
    Score: 0.192
  4. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. J Neuroimaging. 2018 01; 28(1):36-47.
    View in: PubMed
    Score: 0.185
  5. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.157
  6. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci. 2014 Nov 15; 346(1-2):250-4.
    View in: PubMed
    Score: 0.147
  7. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069348.
    View in: PubMed
    Score: 0.061
  8. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Oct; 267(10):2790-2796.
    View in: PubMed
    Score: 0.055
  9. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler. 2020 02; 26(2):177-187.
    View in: PubMed
    Score: 0.053
  10. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e587.
    View in: PubMed
    Score: 0.051
  11. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflamm. 2019 Sep; 6(5).
    View in: PubMed
    Score: 0.051
  12. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.051
  13. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.050
  14. 18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis. Clin Nucl Med. 2018 Sep; 43(9):e289-e295.
    View in: PubMed
    Score: 0.049
  15. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.046
  16. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.044
  17. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.044
  18. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Nov; 127(11):971-980.
    View in: PubMed
    Score: 0.044
  19. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2017 May; 127(5):396-403.
    View in: PubMed
    Score: 0.041
  20. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e200.
    View in: PubMed
    Score: 0.041
  21. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.040
  22. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.037
  23. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
    View in: PubMed
    Score: 0.031
  24. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.031
  25. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.